Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Breast 6Plasma cell 3Gynecologic 3Tumor-Agnostic 2Thoracic 2Other hematologic neoplasm 2Head & Neck 2Genitourinary 2Gastrointestinal 2Other solid neoplasm 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neoplasm Metastasis 2

Interventions

pembrolizumab 56Specimen Handling 28Biopsy 27Magnetic Resonance Spectroscopy 26Paclitaxel 22Blood Specimen Collection 21Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8Taxes 8Ipilimumab 8durvalumab 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
copanlisib × Tumor-Agnostic × 1 year × Clear all
NCT03842228 2026-05-29

COD

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04317105 2026-05-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
54 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡